IMATINIB MESYLATE IN ADVANCED LOW GRADE SOLID TUMORS EXPRESSING IMATINIB MESYLATE TARGETS - ND

ISTITUTO EUROPEO DI ONCOLOGIA0 个研究点开始时间: 2008年4月22日最近更新: 2012年3月19日

试验速览

暂无简介。

•Histological diagnosis of low grade malignant tumor (ie: solitary fibrous malignant tumor,
•hemangioendothelioma, myoepithelioma)
•2. Biomolecular or immunohistochemical evidence of overexpression/activation of any of the
•following Imatinib mesylate targets:
•3. Measurable disease
•4. Unfeasible radical surgical resection of local disease, or surgery unaccepted by the patient, or
•amenable to become less demolitive, or easier, or likely more feasible, after cytoreduction,
•and/or metastatic disease. Debulking surgery before enrolment is allowed. In this case,
•enrolment should occur at least one month after surgery
•5. Performance status (ECOG) 0, 1, 2 or 3
•6. Adequate organ function, defined as the following: total bilirubin <2.5 x ULN, SGOT and
•SGPT <2,5 x UNL (or <5 x ULN if hepatic metastases are present), creatinine <1.5 x ULN.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Previous treatment with any other investigational or not investigational agents within 28 days of
•first day of study drug dosing.
•2. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e.,
•congestive heart failure, myocardial infarction within 6 months of study)
•3. Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or
•active uncontrolled infection).
•4. Known brain metastasis.
•5. Known diagnosis of human immunodeficiency virus (HIV) infection.

发起方